Efficacy of Intravenous Oxytocin to Speed Recovery After THA

What Was Tested

The trial (phase 2) is built around Oxytocin.

It had two arms (groups): Oxytocin (experimental) and Placebo (placebo comparator).

Placebo administered intravenously.

The registry classes the interventions as drug.

More on the Plan

The investigators will utilize a triple-masked, parallel group, randomized design to compare intravenous (IV) oxytocin to placebo to determine IV oxytocin's actions on speed of recovery from physical disability and postoperative pain after Total Hip Arthroplasty (THA).

Who Took Part

80 planned participants were the target.

It was open to people of any sex aged from 18 years up to 75 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Male or female \> 18 and ≤75 years of age. Scheduled for unilateral, primary total hip arthroplasty surgery. Willing to perform the study procedures. Able to read and write English and have a stable residence.

The full record lists 5 inclusion and 10 exclusion criteria; among the exclusions: hypersensitivity to any ingredient in pitocin® (marketed preparation of oxytocin for parenteral injection); latex allergy; women who are pregnant, are currently nursing or lactating, or have been pregnant within 2 years.

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Oxytocin, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant, investigator and outcomes assessor.

It started in 2026-10 with completion listed for 2027-12.

It ran at 1 site in United States.

Its stated primary purpose is basic science.

What Was Measured

Primary outcome: Modeled daily steps trajectory (time frame: 56 days after surgery).

It also tracked 4 secondary outcomes, for example Modeled pain intensity trajectory, Modeled disability assessments and Modeled opioid cessation trajectory.

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Oxytocin in 80 people.

Its status is enrolling by invitation; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Oxytocin compound page, all human trials.